Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the
BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid …

Tuberculosis (TB) is a serious public health problem worldwide. Its situation is worsened by
the presence of multidrug resistant (MDR) strains of Mycobacterium tuberculosis, the …

The causative agent of tuberculosis (TB), Mycobacterium tuberculosis and more recently
totally drug‐resistant strains of M. tuberculosis, display unique mechanisms to survive in the …

Persistent infections involving slow-growing or non-growing bacteria are hard to treat with
antibiotics that target biosynthetic processes in growing cells. Consequently, there is a need …

In addition to the well-known strategies of antibiotic resistance and biofilm formation,
bacterial populations possess an additional survival strategy to endure hostile environments …

Tuberculosis is today amongst the worldwide health threats. As resistant strains of
Mycobacterium tuberculosis have slowly emerged, treatment failure is too often a fact …

Pretomanid is a nitroimidazole antimicrobial active against drug-resistant Mycobacterium
tuberculosis and approved in combination with bedaquiline and linezolid (BPaL) to treat …

Successful chemotherapy against Mycobacterium tuberculosis (Mtb) must eradicate the
bacterium within the context of its host cell. However, our understanding of the impact of this …

An estimated one-third of the world population is latently infected with Mycobacterium
tuberculosis. These nonreplicating, dormant bacilli are tolerant to conventional anti …

Tuberculosis (TB) is the second most deadly infectious disease. Despite potentially curative
pharmacotherapies being available for over 50years, the length of the treatment and the pill …